Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959164 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
A Phase 1 study, sponsored by Mohammed Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02959164: Completed Phase 1 study, sponsored by Mohammed Milhem.
NCT02959164 is a Phase 1 study that has completed, run by Mohammed Milhem. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02959164, a Phase 1 study, has completed, sponsored by Mohammed Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).
Primary Outcome
Non-Hematologic - Any grade 3,4 solid organ toxicity not explainable by another cause in the opinion of the principal investigator
Interventions
- DRUG Decitabine
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 1 |
What the finished NCT02959164 record still lists
NCT02959164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT02959164 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02959164 about?
NCT02959164 is a clinical study titled "Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma". The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).
What is the current status of trial NCT02959164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-12-05. Estimated completion is 2020-10-16.
What interventions are being tested in trial NCT02959164?
The interventions under investigation include: Decitabine (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02959164?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02959164's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI